Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010015/S592

Percepta Bipolar CRT-P; Percepta Quadripolar CRT-P; Serena Bipolar CRT-P; Serena Quadripolar CRT-P; Solara Bipolar CRT-P

Medtronic, Inc. · Decision date Oct 29, 2026

MEDTECHLEDGER EXPLANATIONP010015/S592

What did the FDA decide?

The FDA record for P010015/S592 lists Medtronic, Inc. as applicant and describes the supplement's stated purpose as a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center. The supplement type is a 30-Day Notice with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The listed products are Percepta and Serena bipolar and quadripolar CRT-P devices and Solara bipolar CRT-P, under product code LWP.

The statement identifies a manufacturing-process update at a named supplier site but does not specify which update, the equipment or steps affected, or how these relate to the listed CRT-P models. The decision code is OK30, dated 2026-10-29. The P010015 identifier ties the notice to that PMA file; it is not a new approval of those devices, and the notice does not itself show safety or clinical effectiveness.

FDA approval order statement

a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010015/S592
Regulatory pathway
PMA supplement
Product code
LWP
Decision code
OK30
Decision date
Oct 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable pulse generator, pacemaker (non-CRT).

Product code
LWP
FDA device class
3

For the original device and its historical approval scope, see PMA P010015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010015 · Original PMA

    MEDTRONIC INSYNC(TM) BIVENTRICAL PACING SYSTEM

  2. P010015/S590 · Related supplement

    Percepta Bipolar CRT-P, Percepta Quadripolar CRT-P, Serena Bipolar CRT-P, Serena Quadripolar CRT-P, Solara Bipolar CRT-P

  3. P010015/S592 received

    Application receipt date recorded by FDA.

  4. P010015/S591 · Related supplement

    Percepta Bipolar CRT-P (W1TR01); Percepta Quadripolar CRT-P (W4TR01); Serena Bipolar CRT-P (W1TR02); Serena Quadripolar

  5. P010015/S592 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P010015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010015

Explore the linked device profile

Other records with product code LWP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records